In its first quarter, Novartis managed to boost net sales by 11% year over year to $11.8 billion. The pharmaceutical ...
Novartis acquires MorphoSys for EUR 2.7 billion, a significant premium over the share price, with promising myelofibrosis ...
Under the latest teaming between the two companies, who have worked together since 2010, Novartis will pay $180 million ...
Swiss healthcare giant Novartis (NYSE:NVS) delivered better-than-expected first-quarter results and raised its outlook for ...
Shares of Swiss drugmaker Novartis rallied after the company’s first-quarter sales surpassed analysts’ expectations, and it ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly ...
Novartis is reporting latest earnings.Wall Street analysts expect Novartis will report earnings per share of $1.68.Watch Novartis ...
By Helena Smolak Novartis is scheduled to report results for the first quarter on Tuesday. Here is what you need to know. --CORE OPERATING PROFIT: The ...
Wall Street predict expect Novartis will release earnings per share of $1.68. Watch Novartis stock price move in real-time ahead here. Novartis will be reporting earnings from the most recent ...
Shares of Swiss drugmaker Novartis rallied after the company’s first-quarter sales surpassed analysts’ expectations, and it raised its full-year guidance. Novartis executives touted strong ...